---
title: "Medical information"
description: "Questions on 49 drug and indication pairs, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Covers Biktarvy in HIV-1 infection, Cobenfy in schizophrenia, Darzalex in multiple myeloma, Datroway in HR-positive HER2-negative breast cancer, Dupixent in atopic dermatitis, Eliquis in nonvalvular atrial fibrillation, and 43 further products. 3362 questions quoted from 798 sources."
canonical: "https://www.evicenter.com/medical-information"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Medical information

- [Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection): 57 questions · 13 sources
- [Cobenfy (xanomeline and trospium chloride): Schizophrenia](https://www.evicenter.com/medical-information/cobenfy--schizophrenia): 38 questions · 10 sources
- [Darzalex (daratumumab): All indications](https://www.evicenter.com/medical-information/darzalex): 4 questions · 4 sources
- [Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma): 61 questions · 18 sources
- [Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer): 42 questions · 8 sources
- [Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis): 76 questions · 22 sources
- [Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation): 59 questions · 10 sources
- [Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu): 31 questions · 8 sources
- [Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer): 30 questions · 11 sources
- [Entyvio (vedolizumab): All indications](https://www.evicenter.com/medical-information/entyvio): 25 questions · 4 sources
- [Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis): 37 questions · 12 sources
- [Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management): 88 questions · 6 sources
- [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): All indications](https://www.evicenter.com/medical-information/gardasil-9): 30 questions · 5 sources
- [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination): 40 questions · 6 sources
- [Humira (adalimumab): All indications](https://www.evicenter.com/medical-information/humira): 43 questions · 4 sources
- [Humira (adalimumab): Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis): 24 questions · 3 sources
- [Ibrance (palbociclib): All indications](https://www.evicenter.com/medical-information/ibrance): 64 questions · 10 sources
- [Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer): 28 questions · 10 sources
- [Imbruvica (ibrutinib): All indications](https://www.evicenter.com/medical-information/imbruvica): 42 questions · 10 sources
- [Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma): 58 questions · 30 sources
- [Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis): 73 questions · 12 sources
- [Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer): 28 questions · 8 sources
- [Kisqali (ribociclib): All indications](https://www.evicenter.com/medical-information/kisqali): 26 questions · 2 sources
- [Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer): 57 questions · 15 sources
- [Leqvio (inclisiran): All indications](https://www.evicenter.com/medical-information/leqvio): 57 questions · 15 sources
- [Leqvio (inclisiran): Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia): 17 questions · 7 sources
- [Linzess (linaclotide): All indications](https://www.evicenter.com/medical-information/linzess): 36 questions · 6 sources
- [Linzess (linaclotide): Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation): 19 questions · 4 sources
- [Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro): 32 questions · 3 sources
- [Mounjaro (tirzepatide): Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes): 37 questions · 6 sources
- [Nucala (mepolizumab): All indications](https://www.evicenter.com/medical-information/nucala): 48 questions · 15 sources
- [Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma): 38 questions · 12 sources
- [Nurtec ODT (rimegepant): All indications](https://www.evicenter.com/medical-information/nurtec-odt): 40 questions · 8 sources
- [Nurtec ODT (rimegepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine): 17 questions · 6 sources
- [Ocrevus (ocrelizumab): All indications](https://www.evicenter.com/medical-information/ocrevus): 12 questions · 6 sources
- [Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis): 60 questions · 19 sources
- [Opdivo (nivolumab): All indications](https://www.evicenter.com/medical-information/opdivo): 16 questions · 4 sources
- [Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer): 60 questions · 21 sources
- [Otezla (apremilast): All indications](https://www.evicenter.com/medical-information/otezla): 44 questions · 13 sources
- [Otezla (apremilast): Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis): 27 questions · 14 sources
- [Ozempic (semaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes): 76 questions · 25 sources
- [Paxlovid (nirmatrelvir; ritonavir): All indications](https://www.evicenter.com/medical-information/paxlovid): 63 questions · 7 sources
- [Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19): 41 questions · 12 sources
- [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): All indications](https://www.evicenter.com/medical-information/prevnar-20): 25 questions · 5 sources
- [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults): 21 questions · 11 sources
- [Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine): 71 questions · 11 sources
- [Repatha (evolocumab): All indications](https://www.evicenter.com/medical-information/repatha): 40 questions · 9 sources
- [Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction): 14 questions · 2 sources
- [Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti): 38 questions · 3 sources
- [Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder): 35 questions · 9 sources
- [Rinvoq (upadacitinib): Rheumatoid arthritis](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis): 42 questions · 10 sources
- [Shingrix (Zoster Vaccine Recombinant, Adjuvanted): All indications](https://www.evicenter.com/medical-information/shingrix): 35 questions · 10 sources
- [Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention): 47 questions · 17 sources
- [Skyrizi (risankizumab-rzaa): All indications](https://www.evicenter.com/medical-information/skyrizi): 17 questions · 2 sources
- [Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis): 47 questions · 16 sources
- [Stelara (ustekinumab): All indications](https://www.evicenter.com/medical-information/stelara): 22 questions · 4 sources
- [Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis): 29 questions · 7 sources
- [Taltz (ixekizumab): All indications](https://www.evicenter.com/medical-information/taltz): 41 questions · 9 sources
- [Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis): 33 questions · 5 sources
- [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): All indications](https://www.evicenter.com/medical-information/trelegy-ellipta): 53 questions · 7 sources
- [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease): 32 questions · 7 sources
- [Tremfya (guselkumab): All indications](https://www.evicenter.com/medical-information/tremfya): 34 questions · 15 sources
- [Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis): 32 questions · 16 sources
- [Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer): 47 questions · 15 sources
- [Trulicity (dulaglutide): All indications](https://www.evicenter.com/medical-information/trulicity): 38 questions · 3 sources
- [Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes): 44 questions · 8 sources
- [Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine): 59 questions · 10 sources
- [Vabysmo (faricimab-svoa): All indications](https://www.evicenter.com/medical-information/vabysmo): 66 questions · 18 sources
- [Vabysmo (faricimab-svoa): Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration): 12 questions · 6 sources
- [Verzenio (abemaciclib): All indications](https://www.evicenter.com/medical-information/verzenio): 49 questions · 10 sources
- [Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer): 27 questions · 6 sources
- [Vraylar (cariprazine): All indications](https://www.evicenter.com/medical-information/vraylar): 34 questions · 4 sources
- [Vraylar (cariprazine): Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder): 32 questions · 9 sources
- [Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy): 71 questions · 16 sources
- [Wegovy (semaglutide): All indications](https://www.evicenter.com/medical-information/wegovy): 33 questions · 7 sources
- [Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management): 61 questions · 16 sources
- [Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto): 37 questions · 4 sources
- [Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation): 17 questions · 4 sources
- [Xolair (omalizumab): All indications](https://www.evicenter.com/medical-information/xolair): 36 questions · 8 sources
- [Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma): 38 questions · 10 sources
- [Xtandi (enzalutamide): All indications](https://www.evicenter.com/medical-information/xtandi): 66 questions · 10 sources
- [Xtandi (enzalutamide): Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer): 20 questions · 7 sources
- [Zepbound (tirzepatide): All indications](https://www.evicenter.com/medical-information/zepbound): 33 questions · 1 source
- [Zepbound (tirzepatide): Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management): 33 questions · 7 sources
